Unique ID issued by UMIN | UMIN000005568 |
---|---|
Receipt number | R000006147 |
Scientific Title | A randomized phase II study of efficacy of risendronate for the prevention of letrozole-induced bone mineral loss in post-menopausal breast cancer patients |
Date of disclosure of the study information | 2011/05/07 |
Last modified on | 2020/03/13 00:06:40 |
A randomized phase II study of efficacy of risendronate for the prevention of letrozole-induced bone mineral loss in post-menopausal breast cancer patients
Hiroshima FEmare with Actonel Trial(H-FEAT)
A randomized phase II study of efficacy of risendronate for the prevention of letrozole-induced bone mineral loss in post-menopausal breast cancer patients
Hiroshima FEmare with Actonel Trial(H-FEAT)
Japan |
breast cancer
Breast surgery |
Malignancy
NO
To evaluate the efficacy of risendronate for the prevention of letrozole-induced bone mineral loss in post-menopausal breast cancer patients
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
rate of change from baseline to 12 months in lumbar spine (L1-L4) bone mineral density
rate of change from baseline to 6 months in lumbar spine (L1-L4) bone mineral density
rate of change from baseline to 12 months in total hip bone mineral density
rate of change from baseline to 12 months in bone turnover markers
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
Central registration
2
Treatment
Medicine |
period: 12months
risedronate: 17.5mg/week
letrozole: 2.5mg/day
period: 12months
letrozole: 2.5mg/day
Not applicable |
Not applicable |
Female
Postmenopausal women with hormonereceptor-positive early invasive breast cancer
Patient who completed surgery, chemotherapy and radiotherapy as primary therapy within recent 12 weeks
Eligible for letrozole as adjuvant therapy
T-score is greater than -2.5 in lumbar spine (L1-L4)
Patient who have no fracture in lumber spine and hip
Patient who is not administered any medication that alter bone mineral density
Proved to be eligible for administration of risedronate after consultation of dentistry
Adequate general condition
ECOG PS 0-2
Provided written Informed consent
Metastatic breast cancer
Patient who have lumber spine or hip fracture
Previous history of endocrine therapy for breast cancer within recent 12 months
Patient who is not suitable condition for measurement of bone mineral density
Patient who is planned to undergo dentistry surgery within 6 weeks
Contraindication of study drugs
120
1st name | Morihito |
Middle name | |
Last name | Okada |
Hiroshima University Hospital
Respiratory Surgery
734-8551
1-2-3 Kasumi, Minami-ku, Hiroshima
082-257-5869
morihito@hiroshima-u.ac.jp
1st name | Shinsuke |
Middle name | |
Last name | Sasada |
Hiroshima University Hospital
Breast Surgery
734-8551
1-2-3 Kasumi, Minami-ku, Hiroshima
082-257-5869
http://home.hiroshima-u.ac.jp/genge/
shsasada@hiroshima-u.ac.jp
Hiroshima University
Hiroshima University
Self funding
Japan
Center for Integrated Medical Research, Hiroshima University
1-2-3 Kasumi, Minami-ku, Hiroshima
082-257-1752
protocol@cimr.hiroshima-u.ac.jp
NO
広島大学病院(広島県)、県立広島病院(広島県)、広島総合病院(広島県)
2011 | Year | 05 | Month | 07 | Day |
Unpublished
Completed
2011 | Year | 05 | Month | 06 | Day |
2011 | Year | 05 | Month | 06 | Day |
2011 | Year | 05 | Month | 01 | Day |
2015 | Year | 03 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 09 | Month | 01 | Day |
2015 | Year | 09 | Month | 01 | Day |
2011 | Year | 05 | Month | 07 | Day |
2020 | Year | 03 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006147